Paclitaxel sensitivity in endometrial cancer. Br J Cancer. 2010;103(6):8898. Konecny GE, Venkatesan N, Yang G, Dering J, Ginther C, Finn R, et al. Action of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. Br J Cancer. 2008;98(6):10764. Konecny GE, Santos L, Winterhoff B, Hatmal M, Keeney GL, Mariani A, et al. HER2 gene amplification and EGFR expression in a substantial cohort of surgically staged individuals with nonendometrioid (sort II) endometrial cancer. Br J Cancer. 2009;100(one):895. Oza AM, Eisenhauer EA, Elit L, Cutz JC, Sakurada A, Tsao MS, et al. Phase II examine of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol. 2008;26(26):43195. Fleming GF, Sill MW, Darcy KM, McMeekin DS, Thigpen JT, Adler LM, et al. Phase II trial of trastuzumab in females with sophisticated or recurrent, HER2positive endometrial carcinoma: a Gynecologic Oncology Group research.Aloe emodin medchemexpress Gynecol Oncol. 2010;116(1):150.33. Pecorelli S. Revised FIGO staging for carcinoma of your vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009;105(2):103. 34. Amant F, Mirza MR, Creutzberg CL. Cancer of the corpus uteri. Int J Gynaecol Obstet. 2012;119 Suppl 2:S110. 35. Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, et al. Partnership concerning surgical-pathological chance factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study.3′-O-Methylbatatasin III Cancer Gynecol Oncol. 1991;forty(1):555. 36. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer Jr CE, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):16734. 37. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, et al. Action of the dual kinase inhibitor lapatinib (GW572016) against HER-2overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006;66(three):1630. 38. Tateishi M, Ishida T, Kohdono S, Hamatake M, Fukuyama Y, Sugimachi K. Prognostic influence with the co-expression of epidermal development factor receptor and c-erbB-2 protein in human lung adenocarcinoma. Surg Oncol. 1994;three(2):1093. 39. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al.PMID:23903683 Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(two):1232.Submit your upcoming manuscript to BioMed Central and we are going to assist you at each step:We accept pre-submission inquiries Our selector instrument helps you to locate the most relevant journal We present round the clock buyer help Practical on the internet submission Thorough peer evaluate Inclusion in PubMed and all major indexing companies Maximum visibility for the investigate Submit your manuscript at www.biomedcentral.com/submit
International Journal ofMolecular SciencesArticleMetabolomic Biomarkers in Urine of Cushing’s Syndrome PatientsAlicja Kotlowska one, *, Tomasz Puzyn two , Krzysztof Sworczak three , Piotr Stepnowski four and Piotr Szefer1 2 3*Department of Food Sciences, Faculty of Pharmacy, Healthcare University of Gdansk, Al. Gen. J. Hallera 107, 80-416 Gdansk, Poland; [email protected] Laboratory of Environmental Chemometrics, Faculty of Chemistry, University of Gdansk, ul. Wita Stwosza 63, 80-308 Gdansk, Poland; [email protected] Department of Endocrinology and Internal Medication, Health care University of Gdansk, ul. D binki seven, e 80-211 Gdansk, Poland; [email protected] Department of Environmental Analytics, Institute for Environmental and Human Health and fitness Protection, Faculty of Chemist.